Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A
Department of Endocrinology and Metabolism, Section of Endocrinology, University of Pisa, 56124 Pisa, Italy.
J Clin Endocrinol Metab. 2002 Apr;87(4):1499-501. doi: 10.1210/jcem.87.4.8274.
The follow-up of differentiated thyroid cancer after total thyroidectomy and thyroid ablation is commonly based on serum Tg determination and 131-iodine ((131)I) diagnostic whole-body scan (WBS) performed in the hypothyroid state, 6-12 months after thyroid ablation. Based on the greater sensitivity of Tg measurement, with respect to WBS, the diagnostic yield of diagnostic WBS has been questioned in patients who are off L-T(4) therapy and have undetectable Tg levels. The aim of the present retrospective study was to evaluate the diagnostic relevance of (131)I WBS performed after thyroid remnant ablation, in patients with undetectable serum Tg and off thyroid hormone therapy. The study included 315 of 662 consecutive patients (47.6%) treated in our department between 1980 and 1990, who, at the first control WBS after thyroid ablation, had undetectable serum Tg levels in the hypothyroid state. There were 54 men (17%) and 261 women (83%), with a mean age of 40.9 +/- 13.1 yr (range, 12-76), followed for a mean of 12 +/- 2.8 (range, 9-19) yr. The control WBS was negative in 225 (71.4%) patients and positive for persistent areas of thyroid bed uptake, frequently of very low significance, in 90 (28.6%). No local or distant metastases were discovered. At the last follow-up visit (1999-2000), 281 (89.2%) patients showed complete remission, with undetectable serum Tg off L-T(4) and negative WBS. Persistent thyroid bed uptake, with undetectable levels of Tg, was observed in 29 patients (9.2%) studied during L-T(4) withdrawal. Only 2 patients (0.6%) experienced local recurrence (lymph-node metastases) during their follow-up. In conclusion, our data suggest that the presence of undetectable levels of serum Tg off L-T(4) at the time of the first control WBS after initial treatment, is highly predictive of complete and persistent remission. With the exception of detecting persistent thyroid bed uptake in a minority of cases, the control WBS has never given information that could influence the following therapeutic strategy. On this basis, we propose that the diagnostic (131)I WBS may be avoided in patients with undetectable levels of Tg off L-T(4). These patients may be monitored with clinical examination, neck ultrasound, and serum Tg measurements on L-T(4).
分化型甲状腺癌全甲状腺切除及甲状腺消融术后的随访通常基于甲状腺消融术后6 - 12个月处于甲状腺功能减退状态时进行的血清Tg测定和131碘(131I)诊断性全身扫描(WBS)。鉴于Tg测量相对于WBS具有更高的敏感性,对于停用左甲状腺素(L - T4)治疗且Tg水平检测不到的患者,诊断性WBS的诊断价值受到质疑。本回顾性研究的目的是评估甲状腺残余组织消融后进行的131I WBS在血清Tg检测不到且停用甲状腺激素治疗的患者中的诊断相关性。该研究纳入了1980年至1990年间在我们科室接受治疗的662例连续患者中的315例(47.6%),这些患者在甲状腺消融后的首次对照WBS时,处于甲状腺功能减退状态且血清Tg水平检测不到。其中男性54例(17%),女性261例(83%),平均年龄为40.9±13.1岁(范围12 - 76岁),平均随访时间为12±2.8年(范围9 - 19年)。225例(71.4%)患者的对照WBS为阴性,90例(28.6%)患者的甲状腺床持续摄取呈阳性,其意义通常非常低。未发现局部或远处转移。在最后一次随访(1999 - 2000年)时,281例(89.2%)患者显示完全缓解,停用L - T4后血清Tg检测不到且WBS为阴性。在停用L - T4期间进行研究的29例患者(9.2%)中观察到甲状腺床持续摄取但Tg水平检测不到。随访期间仅有2例患者(0.6%)出现局部复发(淋巴结转移)。总之,我们的数据表明,初始治疗后首次对照WBS时停用L - T4后血清Tg检测不到高度预示完全和持续缓解。除了在少数病例中检测到甲状腺床持续摄取外,对照WBS从未提供可影响后续治疗策略的信息。基于此,我们建议对于停用L - T4后Tg水平检测不到的患者可避免进行诊断性131I WBS。这些患者可通过临床检查、颈部超声以及服用L - T4时的血清Tg测量进行监测。